Moclobemide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Moclobemide: From Depression to Agoraphobia
One-Sentence Summary
Moclobemide is a reversible monoamine oxidase-A inhibitor (RIMA), originally developed and established for the treatment of depression. The TxGNN model predicts it may also be effective for Agoraphobia, with no dedicated clinical trials but 12 supporting publications currently identified — most of which studied moclobemide in the closely related diagnosis of panic disorder (of which agoraphobia is frequently a comorbid subtype), rather than agoraphobia as an independent primary endpoint.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (no ARTG entries); literature context indicates moclobemide’s original approved indication is depression |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L2 |
| Australia Market Status | Not Marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data for moclobemide is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information available in the supporting literature, moclobemide is a reversible, selective inhibitor of monoamine oxidase-A (RIMA). It raises synaptic concentrations of serotonin, noradrenaline and dopamine — the mechanism underlying its established antidepressant effect.
Panic disorder and agoraphobia sit on the same anxiety-disorder spectrum and are frequently comorbid, sharing serotonergic/noradrenergic dysregulation as a proposed common pathway. Several older RCTs tested moclobemide specifically in “panic disorder with agoraphobia” cohorts, which is why the TxGNN model links moclobemide to agoraphobia with a high prediction score.
Importantly, none of the identified trials used agoraphobia itself as the primary diagnostic endpoint — agoraphobia was consistently a comorbid subgroup within panic disorder trials. This is a neighbouring-indication extrapolation rather than direct disease-specific evidence, which is why the evidence level is capped at L2 despite the high TxGNN score. (For reference, two other TxGNN-predicted indications for this drug — neurotic depression and melancholia — carry stronger direct evidence, L1/Proceed with Guardrails, since they map onto moclobemide’s original depression mechanism more directly.)
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10448444 | 1999 | RCT (placebo-controlled) | The British Journal of Psychiatry | Randomised trial of moclobemide, CBT, and their combination in panic disorder with agoraphobia |
| 10361962 | 1999 | RCT (vs clomipramine) | European Archives of Psychiatry and Clinical Neuroscience | Multicentre double-blind trial: moclobemide 450mg/day vs clomipramine 150mg/day in panic disorder with/without agoraphobia (n=135) |
| 16850261 | 2006 | Comparative small trial | Metabolic Brain Disease | SPECT study comparing citalopram and moclobemide effects on resting brain perfusion in social anxiety disorder |
| 28867934 | 2017 | Review | Dialogues in Clinical Neuroscience | Guideline-based review of anxiety disorder treatment, including panic disorder/agoraphobia |
| 32002937 | 2020 | Review | Advances in Experimental Medicine and Biology | Review of current and novel psychopharmacological drugs for anxiety disorders including panic disorder/agoraphobia |
| 7717094 | 1995 | Review | Acta Psychiatrica Scandinavica Supplementum | Review of reversible MAO-A inhibitors (RIMAs) including moclobemide in mental and other disorders |
| 2248064 | 1990 | Review | Acta Psychiatrica Scandinavica Supplementum | Review of MAOI efficacy in panic disorder with agoraphobia, social phobia and other psychiatric disorders |
| 8313401 | 1993 | Review | Clinical Neuropharmacology | Review of reversible MAO-A inhibitors in panic disorder |
| 1498904 | 1992 | Review | Clinical Neuropharmacology | Review of reversible MAO-A inhibitors in panic disorder |
| 7892341 | 1995 | Case report | Psychiatrische Praxis | Case report: treatment-refractory panic disorder with agoraphobia responding to combined imipramine, moclobemide and behaviour therapy |
Australia Market Information
Moclobemide currently has no ARTG entries and is not marketed in Australia (0 licences recorded).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: Supporting evidence consists of one placebo-controlled RCT and one active-comparator RCT, but both used panic disorder (with agoraphobia as a comorbid subgroup) as the primary endpoint rather than agoraphobia itself — a neighbouring-indication extrapolation, not direct disease-specific evidence. This is sufficient to justify a formal research question, but not yet sufficient to progress to a guardrailed proceed decision.
To proceed, the following is needed:
- Detailed mechanism of action data (MOA) — currently a data gap (DG002)
- TGA-approved Product Information / warnings and contraindications — currently a data gap (DG001); note moclobemide is not currently registered on the ARTG
- An agoraphobia-specific trial or subgroup analysis with agoraphobia as the primary (not comorbid) endpoint
- Clarification of a viable Australian regulatory pathway, given the drug is not currently marketed here
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.